Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03455270
Title G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | BEL

Facility Status City State Zip Country Details
Beverly Hills Cancer Center Beverly Hills California 90211 United States Details
Stanford Women Cancer Center Stanford California 94305 United States Details
Northwestern University - Feinberg School of Medicine Chicago Illinois 60611 United States Details
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599-7305 United States Details
Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Sarah Cannon Research Institute at Tennessee Oncology Nashville Tennessee 37203 United States Details
Institut Jules Bordet Brussels 1000 Belgium Details
UZ Leuven Leuven 3000 Belgium Details
MHAT for Womens Health - Nadezhda OOD Sofia 1330 Bulgaria Details
ARENSIA Exploratory Medicine LLC Tbilisi 0112 Georgia Details
ARENSIA Exploratory Medicine Phase I Unit, The Institute of Oncology Chisinau 2025 Moldova, Republic of Details
VU University Medical Center Amsterdam 1081 HV Netherlands Details
University Medical Center Groningen Groningen 9713 GZ Netherlands Details
Erasmus Medical Center Rotterdam 3015 GD Netherlands Details
Spizhenko Clinic Kiev 08112 Ukraine Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field